On May 15, 2025, HCW Biologics Inc. announced that it issued 177,140 shares of common stock after Armistice Capital exercised some pre-funded warrants, and it converted $270,000 in convertible notes into shares at $7.45 each. The conversion provided shares to key executives and included a bonus related to Wugen shares.